The inability to predict a drug’s cardiovascular liability prior to clinical trials or launch has resulted in numerous costly late stage drug development failures and market withdrawals. The aim of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is to update the existing cardiac safety testing paradigm to better evaluate arrhythmia risk. One proposed test of the CiPA panel is a microelectrode array (MEA) assay that tracks drug-induced changes to beating heart cells in a dish. In this webinar, Dr. Daniel Millard, discusses advances in arrhythmia detection to support next-generation CM-MEA assays.
Don't miss a beat with LEAP: An advanced arrhythmia assay Daniel Millard
